7月7日 - ** 制药公司Agios Pharmaceuticals（AGIO.O）的股价在盘前交易中上涨1.2%，至37.82美元
** 该公司表示，美国食品药品监督管理局（FDA）已授予对其用于治疗镰状细胞病的实验性药物mitapivat优先审评资格，该药物正在研发中，用于治疗一种可能引发剧烈疼痛、贫血和器官损伤的遗传性血液疾病
** Agios表示，FDA已将该申请的预期决定日期定为2026年11月1日
** 称米塔皮瓦特有望成为该类药物中首个获批用于治疗镰状细胞病的口服药物
** 该申请基于针对16岁及以上患者的研究结果——AGIO
** 该公司表示，还正在按照FDA的要求开展一项确认性试验
** 截至上一交易日收盘，该股年内累计涨幅约为37%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.